KR20220110209A - 이중 il-2r 및 il-7r 결합 화합물 - Google Patents

이중 il-2r 및 il-7r 결합 화합물 Download PDF

Info

Publication number
KR20220110209A
KR20220110209A KR1020227018973A KR20227018973A KR20220110209A KR 20220110209 A KR20220110209 A KR 20220110209A KR 1020227018973 A KR1020227018973 A KR 1020227018973A KR 20227018973 A KR20227018973 A KR 20227018973A KR 20220110209 A KR20220110209 A KR 20220110209A
Authority
KR
South Korea
Prior art keywords
ligand
amino acid
acid sequence
ligands
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227018973A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 제이 다우어
마이클 씨 니델스
로날드 더블유 바렛
앨리스 브이 바커
스티븐 이 크월라
Original Assignee
메디카인 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디카인 인코포레이티드 filed Critical 메디카인 인코포레이티드
Publication of KR20220110209A publication Critical patent/KR20220110209A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227018973A 2019-11-05 2020-11-04 이중 il-2r 및 il-7r 결합 화합물 Withdrawn KR20220110209A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962930758P 2019-11-05 2019-11-05
US62/930,758 2019-11-05
US202062969432P 2020-02-03 2020-02-03
US62/969,432 2020-02-03
US202063041158P 2020-06-19 2020-06-19
US63/041,158 2020-06-19
US202063071946P 2020-08-28 2020-08-28
US63/071,946 2020-08-28
PCT/US2020/058969 WO2021092081A1 (en) 2019-11-05 2020-11-04 Dual il-2r and il-7r binding compounds

Publications (1)

Publication Number Publication Date
KR20220110209A true KR20220110209A (ko) 2022-08-05

Family

ID=75686972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018973A Withdrawn KR20220110209A (ko) 2019-11-05 2020-11-04 이중 il-2r 및 il-7r 결합 화합물

Country Status (11)

Country Link
US (2) US11248030B2 (enExample)
EP (1) EP4055036A4 (enExample)
JP (2) JP7427287B2 (enExample)
KR (1) KR20220110209A (enExample)
AU (2) AU2020378282B2 (enExample)
BR (1) BR112022008750A2 (enExample)
CA (1) CA3160466A1 (enExample)
IL (1) IL292803A (enExample)
MX (1) MX2022005404A (enExample)
TW (1) TW202132330A (enExample)
WO (1) WO2021092081A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021201047B2 (en) * 2018-08-06 2022-02-17 Medikine, Inc. Il-2 receptor binding compounds
BR112021002250A2 (pt) * 2018-08-06 2021-07-20 Medikine, Inc. compostos de ligação ao receptor de il-2
JP7427286B2 (ja) * 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
IL292803A (en) * 2019-11-05 2022-07-01 Medikine Inc Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof
CA3166816A1 (en) * 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
CA3197344A1 (en) * 2020-11-04 2022-05-12 William J. Dower Il-2r.beta.yc binding compounds and uses thereof
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) * 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2024054874A1 (en) * 2022-09-06 2024-03-14 Medikine, Inc. Use of il-2r-beta-gamma agonist peptides in cell manufacturing
WO2024054870A1 (en) * 2022-09-06 2024-03-14 Medikine, Inc. Use of il-7r-alpha-gamma agonist peptides in cell manufacturing

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
ATE500267T1 (de) * 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
US20120210458A9 (en) * 2009-02-27 2012-08-16 Yongwei Cao Isolated Novel Nucleic Acid and Protein Molecules from Corn and Methods of Using Thereof
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CA2820956C (en) 2010-12-10 2016-05-03 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
CN102775496B (zh) * 2011-05-13 2014-10-08 中国医学科学院基础医学研究所 靶向清除hiv/siv的复合药物
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
PT3172227T (pt) 2014-07-21 2019-12-06 Delinia Inc Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
AU2015301936B2 (en) * 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2017213659B2 (en) 2016-02-05 2024-04-18 Washington University Compositions and methods for targeted cytokine delivery
CN109562143A (zh) * 2016-05-06 2019-04-02 王牧林 白细胞介素组合及其用途
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
AU2017378308A1 (en) 2016-12-13 2019-06-20 Delinia, Inc. Multivalent regulatory T cell modulators
BR112021002250A2 (pt) 2018-08-06 2021-07-20 Medikine, Inc. compostos de ligação ao receptor de il-2
JP7427286B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
IL292803A (en) * 2019-11-05 2022-07-01 Medikine Inc Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof
MX2022009302A (es) 2020-02-03 2022-11-16 Medikine Inc Compuestos de unión a il-7r¿.
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds

Also Published As

Publication number Publication date
CA3160466A1 (en) 2021-05-14
US11248030B2 (en) 2022-02-15
BR112022008750A2 (pt) 2022-07-19
IL292803A (en) 2022-07-01
US20220119465A1 (en) 2022-04-21
JP2024056696A (ja) 2024-04-23
EP4055036A1 (en) 2022-09-14
AU2020378282B2 (en) 2023-05-18
MX2022005404A (es) 2022-09-09
AU2023214299A1 (en) 2023-10-26
JP7427287B2 (ja) 2024-02-05
US20210130424A1 (en) 2021-05-06
TW202132330A (zh) 2021-09-01
JP2022553826A (ja) 2022-12-26
WO2021092081A1 (en) 2021-05-14
AU2020378282A1 (en) 2022-06-09
EP4055036A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
US11248030B2 (en) Dual IL-2R and IL-7R binding compounds
JP7427286B2 (ja) ＩＬ－２ＲβγＣ結合化合物
US11965015B2 (en) IL-7R-α-γ binding compounds
KR20230097168A (ko) IL-2Rβγc 결합 화합물 및 이의 용도
US20220119492A1 (en) Il-2r-beta-gamma binding compounds and uses thereof
CN116829579A (zh) Il-2r和il-7r双重结合化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220603

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220705

Comment text: Request for Examination of Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20240826

WITB Written withdrawal of application